![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » SIRION THERAPEUTICS ACQUIRES U.S. LICENSE TO DEVELOP NEW TREATMENT FOR EYE DISEASE
SIRION THERAPEUTICS ACQUIRES U.S. LICENSE TO DEVELOP NEW TREATMENT FOR EYE DISEASE
June 22, 2006
Sirion Therapeutics, Inc., an ophthalmic-focused pharmaceutical company, announced today that it has reached an exclusive licensing agreement with Senju Pharmaceutical Co., Ltd. of Japan for the U.S. rights to develop and market a topical ophthalmic emulsion containing the steroid compound difluprednate for the treatment of inflammatory eye diseases.
Drug
Newswire
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct